Article

Long-term safety of anecortave acetate studied in 24-month analysis

Alcon Laboratories Inc. reported 24-month data from its comparative study of anecortave acetate suspension (Retaane 15 mg) versus photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis Ophthalmics/QLT Inc.) in the treatment of wet age-related macular degeneration (AMD).

The primary aim of the 24-month analysis was to confirm the long-term safety of anecortave acetate suspension, according to Alcon. Safety information from this study showed that no clinically relevant safety issues were observed due to the drug or the posterior juxtascleral depot procedure during the entire course of the study, the company said. Ocular and non-ocular adverse events were reported at similar rates in both arms of the study, reported the company.

In addition to the safety data, Alcon said 2-year data continued to show anecortave acetate suspension is clinically equivalent to PDT with verteporfin. Furthermore, the mean visual acuity for both treatment groups was clinically stable from month 12 to 24.

"We believe these data indicate that Retaane suspension has the potential to play a unique role in the chronic treatment of wet AMD," said Stella Robertson, PhD, Alcon's vice president, ophthalmic development, Fort Worth, TX. "We continue to have discussions with the FDA and other regulatory agencies around the world to gain approval of this drug."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.